{"id":"f620b0f5-bb00-5de7-8fcd-c97e67bc80e1","stable_key":"252872b9-233f-5692-b72b-c8930ba0cfb7:sil-protease-inhibitor-quadruples-exposure","predicate":"increases","statement":"In six HIV-infected patients at steady state on indinavir a single 25 milligram dose of sildenafil did not significantly alter plasma indinavir concentrations, but the geometric mean area under the sildenafil concentration curve of 1631 nanograms per millilitre hour was 4.4 times higher than data from historical controls given either 50 or 100 milligrams and dose normalised to 25 milligrams, and in a parallel study indinavir was a potent inhibitor of sildenafil hepatic metabolism in vitro with a half-maximal inhibitory concentration of 0.39 micromolar, so that the mechanism of the increase is inhibition of hepatic metabolism and a lower starting dose may be more appropriate in this setting.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"644dcaaf-0936-5b78-b2ab-032d9f6d47d8","mechanism_event_label":"A drug that blocks the same liver enzyme left more than four times as much of it in the blood.","subject":{"id":"c9dce63e-ebd8-5ea7-b2c4-73d01d767bc4","slug":"indinavir","display_name":"Indinavir","entity_type_key":"drug"},"object":{"id":"fe62cf8d-5f89-5e19-bc36-03ad3c9063b7","slug":"sildenafil","display_name":"Sildenafil","entity_type_key":"drug"},"evidence_count":1,"mechanism_event":{"id":"644dcaaf-0936-5b78-b2ab-032d9f6d47d8","stable_key":"252872b9-233f-5692-b72b-c8930ba0cfb7:sil-protease-inhibitor-quadruples-exposure-event","event_type":"observed_intervention","label":"A drug that blocks the same liver enzyme left more than four times as much of it in the blood.","description":"In six HIV-infected patients at steady state on indinavir a single 25 milligram dose of sildenafil did not significantly alter plasma indinavir concentrations, but the geometric mean area under the sildenafil concentration curve of 1631 nanograms per millilitre hour was 4.4 times higher than data from historical controls given either 50 or 100 milligrams and dose normalised to 25 milligrams, and in a parallel study indinavir was a potent inhibitor of sildenafil hepatic metabolism in vitro with a half-maximal inhibitory concentration of 0.39 micromolar, so that the mechanism of the increase is inhibition of hepatic metabolism and a lower starting dose may be more appropriate in this setting.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"54e95ff1-4ffa-5e6f-a4cb-b47e5d2a5bda","slug":"cyp3a4","display_name":"Human cytochrome P450 3A4","entity_type_key":"protein"},"role":"shared_enzyme","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d40bf9f7-6cd8-5c81-a131-234a2f12bc3c","slug":"presystemic-hepatic-metabolism","display_name":"Pre-systemic hepatic metabolism","entity_type_key":"cellular_process"},"role":"inhibited_process","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"4de96319-6ac4-5e9f-92f2-8771dd79bb54","slug":"ritonavir","display_name":"Ritonavir","entity_type_key":"drug"},"role":"related_inhibitor","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"736a4c55-284d-5361-bf7a-459544e16af1","slug":"systemic-blood-pressure","display_name":"Systemic arterial blood pressure","entity_type_key":"cellular_process"},"role":"downstream_concern","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"c9dce63e-ebd8-5ea7-b2c4-73d01d767bc4","slug":"indinavir","display_name":"Indinavir","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"fe62cf8d-5f89-5e19-bc36-03ad3c9063b7","slug":"sildenafil","display_name":"Sildenafil","entity_type_key":"drug"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/sildenafil-research/10546851.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a789c249a680590fd363d884785a531062441be8e2442ec872fa832dc43b7504\", \"start_char\": 0, \"end_char\": 2556, \"text_sha256\": \"a789c249a680590fd363d884785a531062441be8e2442ec872fa832dc43b7504\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Open pharmacokinetic study in six patients at steady state on a protease inhibitor, with a parallel in vitro metabolism arm","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"A single 25 milligram dose of sildenafil added to steady-state indinavir, with plasma sampling to eight hours","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Six patients and no concurrent control group: the sildenafil exposure is compared with dose-normalised historical controls rather than with the same patients off indinavir.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Sildenafil research collection; topical membership is not evidence of a direct clinical effect, and the drug is recorded separately from its N-desmethyl metabolite and its target enzyme from the homologous retinal PDE6.","comparator":null,"unit":null,"notes":"","entity":{"slug":"sildenafil","display_name":"Sildenafil","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A drug that blocks the same liver enzyme left more than four times as much of it in the blood.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[sil-p10546851] Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. (1999). https://pubmed.ncbi.nlm.nih.gov/10546851/ DOI: 10.1097/00002030-199910220-00001","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Systemic circulation and liver microsomes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"082e1d84-b512-5f4a-b02d-a58018b78db0","evidence_kind":"source_excerpt","locator":"Lines 470-481","start_line":470,"end_line":481,"excerpt":"### sil-protease-inhibitor-quadruples-exposure\nIn six HIV-infected patients at steady state on indinavir a single 25 milligram dose of sildenafil did not significantly alter plasma indinavir concentrations, but the geometric mean area under the sildenafil concentration curve of 1631 nanograms per millilitre hour was 4.4 times higher than data from historical controls given either 50 or 100 milligrams and dose normalised to 25 milligrams, and in a parallel study indinavir was a potent inhibitor of sildenafil hepatic metabolism in vitro with a half-maximal inhibitory concentration of 0.39 micromolar, so that the mechanism of the increase is inhibition of hepatic metabolism and a lower starting dose may be more appropriate in this setting.\nCondition category: machinery_impairment\nnutrient_topic: Sildenafil research collection; topical membership is not evidence of a direct clinical effect, and the drug is recorded separately from its N-desmethyl metabolite and its target enzyme from the homologous retinal PDE6.\nplain_language: A drug that blocks the same liver enzyme left more than four times as much of it in the blood.\norganism: Human\ntissue_or_cell_type: Systemic circulation and liver microsomes\nexperimental_model: Open pharmacokinetic study in six patients at steady state on a protease inhibitor, with a parallel in vitro metabolism arm\nlimitations: Six patients and no concurrent control group: the sildenafil exposure is compared with dose-normalised historical controls rather than with the same patients off indinavir.\nexposure: A single 25 milligram dose of sildenafil added to steady-state indinavir, with plasma sampling to eight hours\nevidence_span: {\"source_cache\": \"artifacts/sildenafil-research/10546851.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a789c249a680590fd363d884785a531062441be8e2442ec872fa832dc43b7504\", \"start_char\": 0, \"end_char\": 2556, \"text_sha256\": \"a789c249a680590fd363d884785a531062441be8e2442ec872fa832dc43b7504\"}\n[sil-p10546851] Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. (1999). https://pubmed.ncbi.nlm.nih.gov/10546851/ DOI: 10.1097/00002030-199910220-00001","model_system":"Open pharmacokinetic study in six patients at steady state on a protease inhibitor, with a parallel in vitro metabolism arm","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [sil-p10546851] Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. (1999). https://pubmed.ncbi.nlm.nih.gov/10546851/ DOI: 10.1097/00002030-199910220-00001","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"c6c2a590-1f8f-5fac-b2c7-3aae0440b9fd","stable_key":"import-252872b9-233f-5692-b72b-c8930ba0cfb7","title":"Sildenafil: the enzyme it occupies instead of the substrate, why it cannot start a signal it can only preserve, the organic nitrate interaction that follows from that, the homologous retinal enzyme ten-fold away, and the pulmonary circulation where the same mechanism became a second indication (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"bc81793d20d20d2eaad9cb530b70695d8d8778a3d7136e24715ac3369b939953","revision_id":"301732e1-2446-5b67-b3bd-580164b85b05","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}